Animal model for identifying agents that inhibit or enhance CTLA4 signaling
View Patent ↗The present invention relates to a non-human transgenic animal, particularly a knock in mouse, whose genome comprises a heterologous, chimeric CTLA4 gene. The chimeric CTLA4 gene comprises exon 2 of the human CTLA4 gene, exon 1 and exon 4 of the non-human animal, and exon 3 of the CTLA4 gene of the non-human animal, or preferably, exon 3 of the human CTLA4 gene. The invention also relates to methods by which the transgenic mice are used to screen for monoclonal antibodies or other molecules that enhance immunity to tumors and infectious agents by interacting with the human CTLA4 receptor. The transgenic mice of the present invention are also useful for screening for monoclonal antibodies or other molecules that inhibit autoimmunity and transplant rejection.
1. A method for screening candidate therapeutic agents, which engage with human CTLA4 molecules and inhibit or block the development of cancers, comprising:
(a) injecting cells, which are capable of developing into a tumor, into a transgenic mouse whose genome comprises a nucleic acid encoding a humanized CTLA4 receptor and whose T cells express the humanized CTLA4 receptor, wherein said humanized CTLA4 receptor comprises the extracellular domain of a human CTLA4 receptor, and said nucleic acid comprises exon 2 of a human CTLA4 receptor gene, and exons 1, 3, and 4, of a mouse or human CTLA4 receptor gene,
(b) administering a candidate agent to said mouse, and
(c) monitoring the growth of said tumor.
2. The method according to claim 1 , wherein the candidate therapeutic agent comprises at least one agent chosen from the group consisting of peptides, small organic molecules, peptidomimetics, and antibodies.
3. The method according to claim 2 , wherein the candidate therapeutic agent comprises an antibody.
4. The method according to claim 3 , wherein the candidate therapeutic agent comprises a monoclonal antibody.